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Contribution of human uropontin to inhibition of calcium oxalate
crystallization. Uropontin (UP) is known to inhibit the growth and
nucleation of calcium oxalate monohydrate (COM) crystals, and it also
impedes attachment of calcium oxalate crystals to cultured renal epithelial
cells. However, its role in normal defense against renal crystallization, and
in pathogenesis of nephrolithiasis is unclear. In this study we determined
the effect of UP on aggregation of COM crystals as well as the inhibitory
activity of UP on COM crystal growth and nucleation in a series of normal
subjects, in order to assess the potential of UP as an important urinary
inhibitor. The mean urinary excretion of UP measured by ELISA was
185 6 12 nmol/24 hr (mean 6 SEM) with a mean urine UP concentration
of 131 6 13 nM. Uropontin isolated by immunoaffinity chromatography
was a very potent inhibitor of COM crystal aggregation, with a mean UP
concentration of 28 6 4 nM required for a 50% reduction in aggregation.
The kDa for COM crystal growth inhibition determined from Langmuir
type isotherms was 21 6 3 nM and the concentration required for 50%
reduction in COM crystal growth rate was 16 6 2 nM. Inhibition of
secondary nucleation was measured at a single concentration of 200 nM,
which reduced the nucleation rate to 42 6 3% of control. Using a
theoretical model of growth and aggregation inhibition at varying urine
flow rates, we showed that inhibitory activity of UP would be significant for
all subjects over a wide range of urine flow rates. Overall, UP is a potent
inhibitor of COM aggregation as well as growth and nucleation. The
urinary concentration of UP is in the range in which its contribution to
inhibition of growth and aggregation are likely to be substantial. Thus, UP
appears to be an important natural defense against renal crystallizations
and nephrolithiasis.
Although urine of normal people is supersaturated with respect
to calcium oxalate monohydrate (COM) [1], the most common
crystalline component of human renal stones [2], only a small
fraction of people form stones [3]. One reason why urine super-
saturation need not lead invariably to crystalluria, stone forma-
tion, and nephrocalcinosis is that urine inhibits the crystallization
of calcium oxalate [1]. Much of this inhibition resides in non-
dialyzable molecules [4], which differ from one another in the
specific aspects of crystallization that they inhibit. For example,
Tamm-Horsfall protein inhibits aggregation, but not growth or
nucleation of COM crystals [5–7], whereas nephrocalcin inhibits
each of these aspects of crystallization [5, 7, 8]. Uropontin (UP),
the urinary form of osteopontin [9], reduces growth [10] and
nucleation [11] of COM crystals, as well as crystal attachment to
renal epithelial cells [12], at concentrations lower than those
found in urine [13].
Our present aim was to place the functional activities of UP in
a clinical context by comprehensively analyzing its effects on
COM crystallization. The range of crystallization events UP
interferes with is not yet certain. As uncertain is the relationship
between urine UP concentrations and the concentrations need for
UP to inhibit aggregation, growth, and nucleation of COM. In this
study, we have measured the effects of UP on crystal aggregation
to complete our knowledge of its inhibition capacities. In order to
determine the extent to which UP can inhibit COM crystalliza-
tions at its usual urine concentrations, we also determined the
range over which UP excretion and inhibition varied among this
group of normals. We included measurements of growth and
nucleation inhibition so that we could directly compare their
normal range of inhibitory activities with inhibition of aggregation
by UP.
METHODS
Urine collections
We studied 14 samples of UP from 13 non-stone forming
subjects (Table 1). We studied two UP samples from one of the
male subjects. Twenty-four hour urines were collected as outpa-
tients on a random diet. Subjects were not on any medications at
the time of urine collection. The urines were not refrigerated
during collection, thymol or thimerosal were used as a preserva-
tive.
Uropontin purification and assay
Uropontin was purified by immunoaffinity chromatography
using monoclonal antibody ZH2 coupled to Sepharose beads as
previously described [9]. Urine proteins were partially fraction-
ated by absorption to DEAE-cellulose and batch eluted [9] prior
to immunopurification. Quantitative analysis of UP concentra-
tions in urine samples was performed by ELISA using a mono-
specific polyclonal antiserum to UP [14]. Samples of UP were
assayed for protein concentration using ninhydrin reactivity after
alkaline hydrolysis [15].
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Crystal growth inhibition
Calcium oxalate monohydrate growth was measured using a
seeded crystal assay previously described [15]. Briefly, COM seeds
were added to 2 ml of a metastable calcium oxalate solution,
contained in a quartz cuvette, maintained at 37°C, and magneti-
cally stirred. Oxalate consumption was initiated by the seed
crystals and was monitored for 400 seconds with a continuous
recording spectrophotometer at 214 nm. The rate of oxalate
consumption follows second order kinetics, and the velocity of the
reaction can be derived from the integrated rate equation [15].
The assay was run with and without UP in an alternating fashion
such that each UP sample was sandwiched by two control
measurements. Uropontin (UP) was added to the system in the
range of 2 to 200 nM/liter, and duplicates were run for each UP
sample at all concentrations. The peptide molecular weight of
uropontin was assumed to be 33 kDa [9].
We evaluated inhibition using two different mathematical mod-
els. One model of inhibition, which we have often used is to
calculate the kDa from a standard Langmuir type isotherm plot
[15, 16]. Such values represent the empirical association constant
of UP with an assumed single growth site to which UP can
reversibly adsorb, and in adsorbing to the site, remove the site as
a place for growth to occur. These plots usually include a few very
high values of the isotherm, at low levels of inhibition. This is
because the term is v/(v02v) where v0 and v are growth velocity in
the absence and presence of UP respectively, so that velocity at
low inhibition yields v very close to v0 and a large number for the
Langmuir term. Regressions can be highly influenced by a few
extreme values derived from measurements at low fractional
inhibition, and because the kDa is calculated from the regression
kDa becomes subject to the same extreme values.
Another model is a plot of growth inhibition against protein
concentration; though simple data plots are not linear, a plot of
log growth inhibition against log UP concentration yields a good
linear fit. The slope from such log log plots is an alternative
estimate of UP inhibition of growth. Moreover, the concentration
giving 50% inhibition, derived from such a regression, should
correlate with the kDa, as kDa is an estimate of the concentration
at which 50% of the crystal growth sites are bound by inhibitor
[16]. These plots are not as remarkably influenced by high outliers
at low inhibition, as is the Langmuir type plot.
Aggregation inhibition
Aggregation inhibition studies were performed on 12 of the 14
samples obtained. Calcium oxylate monohydrate crystal slurries
0.8 mg/ml (average crystal diameter of 2 to 5 mm) were prepared
in 200 mM NaCl, 10 mM acetate, pH 5.7, and magnetically stirred
at 1100 RPM overnight at 37°C. The crystals and solution come to
equilibrium so crystals no longer dissolve or grow [5]. The slurry
was then added to multiple tubes, each used for a single assay.
Uropontin samples were added to the stirred slurry one hour prior
to assay. A 2 ml aliquot of the crystal slurry was transferred to a
quartz cuvette maintained at 37°C, and was constantly monitored
at 620 nm. In this system OD620 was proportional to the mass of
crystal per unit volume [5]. The slurry was initially stirred at 1100
RPM to obtain a stable baseline, then crystal aggregation was
induced by slow stirring at 500 RPM for 180 seconds. Stirring was
stopped and particle sedimentation monitored. The rate of fall in
OD620, measured as the slope of the straight portion of the plot of
OD versus time, reflects the average particle size and was taken as
a measure of aggregation [5]. The assay was run with and without
UP added to the slurry in an alternating fashion. Uropontin was
used in concentrations ranging from 1 to 100 nM, and duplicates
were run for each UP at every concentration. The UP inhibition
of aggregation was quantified by plotting log UP concentration
versus log aggregation inhibition and estimating the 50% inhibi-
tion concentration from the slope of the regression line.
Nucleation inhibition
Nucleation studies were performed on five samples of UP.
Secondary COM nucleation from preformed COM crystals was
measured using a stirred suspension of COM seeds, 10 to 20 mm
in length along their long axes [7]. The seeds were added to 5 ml
of a metastably supersaturated solution of 0.5 mM Ca, 0.5 mM
oxalate, 150 mM NaCl, buffered with 10 mM Hepes, pH 7.2.
Calcium concentration was measured continuously by a calcium
ion specific electrode. After seed addition, nucleation occurs, and
results in consumption of calcium which is sensed by the calcium
Table 1. Uropontin (UP) excretion and inhibitory activity
Subject Age Sex nmol/24 hr nmol/liter gkDa nM g50% nM a50% nM nr%
1 32 m 220 142 18 24 30 41.3
2 67 m 230 133 32 12 15 34.5
2 67 m 232 129 36 26
3 23 f 140 95 14 14 26 50.4
4 33 f 170 136 34 26 22 43.0
5 33 f 120 92 5 6 16 40.3
6 23 f 159 91 26 15 51
7 40 m 193 203 25 22 23
8 28 m 257 257 12 10 13
9 41 m 188 130 36 19 48
10 23 f 111 91 18 12 20
11 25 m 219 154 3 3 52
12 38 m 175 67 16 10 21
13 57 m 180 121 25 23
Mean6SEM 185 6 12 131 6 13 21 6 3 16 6 2 28 6 4 42 6 3
Abbreviations are: m, male; f, female; nmol/24 hr; nmoles of UP excreted per 24 hours; conc, UP concentration in nmole/liter; gkDa, growth inhibition
kDa in nM; g50% concentration of UP to reduce growth rate to 50% of control, in mM; a50%, concentration of UP to reduce aggregation to 50% of
control, in nM; nr%, nucleation rate expressed as percent of concomitant control values.
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electrode. Servo-regulated micropumps provided calcium and
oxalate in equimolar amounts, keeping calcium concentration and
supersaturation constant. During nucleation, as opposed to crystal
growth, consumption of calcium is log linear with time in such a
supersaturation clamped system [7, 17]. The slope of log calcium
consumption versus time is used as an index of nucleation rate.
The assay was run with UP paired to a control with only buffer
added. Four of the five protein samples were done in duplicate.
From the ratio of nucleation rate in the presence of UP to
nucleation rate from the control, we calculated a percent inhibi-
tion, at a single UP concentration of 200 nM.
Statistical analysis
Means, regressions, t-tests, and analysis of covariance were
calculated using standard technology (Systat; SPSS Corporation,
Chicago, IL, USA). In all cases, regression slopes were evaluated
using ANOVA, and slopes were used for further calculations only
when F values were significant (P , 0.05).
Estimates of UP inhibition of COM growth and aggregation in
vivo were made using the individual log log regression equations.
The UP concentration was calculated for five assumed urine
volumes, of 0.5, 1, 1.5, 2, and 2.5 liter/24 hr duration, using the
measured 24-hour UP excretion for the subject. These UP
concentrations were then entered into the log log regression
equations to obtain predicted percent inhibitions of growth and
aggregation. The results were plotted as percent inhibition against
the half inhibition UP concentration, with differing symbols for
each of the five urine flow rates, to derive a picture of in vivo UP
effects over our range of normals.
RESULTS
Growth inhibition
Calcium oxalate monohydrate crystal growth rate fell smoothly
with UP concentration over the range of 2 to 200 nM, and a double
log plot produced a linear regression (Fig. 1) for the whole group
of measurements. Each of the 14 UP samples had a significant
individual log log regression slope (not shown). The separate
Langmuir plots for all 14 samples also had significant regressions,
from which kDa values could be calculated (Table 1).
The regression equations for the Langmuir plots, unlike the
slopes of the log plots, can be strongly influenced by a small
number of very high values for the Langmuir term at low levels of
inhibition. For this reason, we compared the two different meth-
ods for quantifying UP crystal growth inhibition. From the log
plots, we calculated a regression slope for each sample. Using the
regression, we calculated the UP concentration predicted to
produce 50% growth inhibition. The Langmuir kDa is itself the
UP concentration predicted by that model to produce a 50%
inhibition [16]. The two indices (Fig. 2) are correlated (r2 5 0.574,
F 5 58, P 5 0.002), showing that the two models for quantifying
growth inhibition give related values, in or close to the same
general range. The values for kDa (Table 1) and half inhibition
were reproducible in the one male studied in duplicate.
From the log log regression equation and the UP excretion for
each subject, we constructed an estimate of likely in vivo effects of
UP at five assumed 24-hour urine volumes, assuming that UP
excretion did not vary with urine flow rate (Methods). Growth
rate ranged from a low of 5% of control for the most inhibitory
UP samples at 0.5 liter daily urine volume, to as high as 40% for
Fig. 1. Calcium oxalate monohydrate (COM) crystal growth inhibition.
The x-axis is the uropontin (UP) concentration (nM) plotted on a log scale.
The y-axis is the growth velocity in the presence of UP as a percent of the
control without inhibitor, on a log scale. Results of all UP samples tested
are included on the graph. The solid line is the linear regression (r2 5 0.56,
F 5 274, P , 0.001).
Fig. 2. Correlation of kDa with calcium oxalate monohydrate (COM)
crystal growth half inhibition concentration. The x-axis is the concentra-
tion of half inhibition of COM crystal growth obtained from the log-log
plot of growth inhibition versus concentration of uropontin (UP) as in the
Methods section. The y-axis is the kDa estimated from the Langmuir
isotherm. The solid line is the linear regression (r2 5 0.574, F 5 16, P 5
0.002).
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the UP samples with the lowest growth inhibition at 2.5 liter of
daily urine flow (Fig. 3). Thus, although UP inhibition of growth
can be expected to vary with urine volume and the half inhibition
concentration, it seems considerable, even at the upper extremes
of volume and at the higher half inhibition concentrations.
Aggregation inhibition
Aggregation rate fell smoothly with UP concentration (Fig. 4)
when plotted on a double log scale. Each of the 12 UP samples
had a significant individual log log regression slope (data not
shown). Values for UP half inhibition concentration (Table 1)
ranged form 13 to 52 nM. From the slope of the individual log
inhibition plots, we calculated the expected inhibition from the
excretion rates (Table 1) for five assumed urine volumes (Fig. 5).
As was the case for growth inhibition, at the lowest volume the
aggregation rate was only 10% of control, whereas at higher
volumes aggregation rose to nearly 50% of controls. There was no
correlation between the concentration of UP required for 50%
inhibition of growth and aggregation (r2 5 0.00, F 5 0.001, P 5
0.98)
Nucleation inhibition
All five UP samples inhibited secondary nucleation (Fig. 6 and
Table 1) at 200 nM, as shown by the slower consumption of
calcium and oxalate from solution. Because log consumption
varies linearly with time, we calculated the slopes of the log
regressions (Methods) as an index of nucleation, and calculated
the ratio of UP to control slopes as an index of inhibition.
Inhibition of nucleation, expressed as the percent of the nucle-
ation rate in the absence of UP, ranged from 34 to 50% among
five subjects (Table 1). There was no correlation between kDa for
aggregation or growth and the percent inhibition of nucleation
(Table 1). At concentrations of 20 to 50 nM, sufficient for
inhibition of growth and aggregation, we have found no inhibition
of nucleation (not shown).
DISCUSSION
Uropontin inhibits COM aggregation at concentrations similar
to those that inhibit COM growth, within the range of 5 to 40 nM.
Although past studies have documented the inhibition of growth
by UP and osteopontin and nucleation of COM by osteopontin,
none to date have quantitated inhibition of aggregation. Given
that it inhibits COM aggregation, UP is the first fully defined urine
macromolecule that can inhibit all three aspects of COM crystal-
lization. Nephrocalcin, an acidic urinary glycoprotein also inhibits
all three aspects of COM crystallization [5, 7, 8], but has not, to
date, been fully purified or sequenced. Uropontin inhibits aggre-
gation and growth at approximately one tenth the concentration
at which NC is active [5, 8] and the excretion rate of these proteins
is similar on a molar basis. Uropontin inhibition of secondary
nucleation is approximately the same for nephrocalcin (NC) [7].
Tamm-Horsfall protein is a very well defined urine inhibitor, but
acts only on aggregation. Tamm-Horsfall protein (THP) and UP
have similar half inhibition concentrations for aggregation, ap-
proximately 10 to 20 nM for THP and 15 to 50 nM for UP.
However, THP aggregation inhibition is reduced at high THP
concentrations by a combination of low pH and high sodium
concentrations, due to THP self aggregation [6]. In the present
Fig. 3. Calcium oxalate monohydrate (COM) crystal growth inhibition
as a function of uropontin (UP) inhibitory activity and urine flow. The
x-axis is the growth half inhibition concentration (nM) as estimated from
the log-log plot of growth inhibition versus concentration of UP (note
x-axis is on a powered scale). The y-axis is the growth velocity expressed as
percent control estimated for 5 different assumed 24-hr urine volumes:
(l) 0.5 liters of urine/24 hr; (F) 1 liter/24 hr; () 1.5 liters/24 hr; () 2
liters/24 hr; () 2.5 liters/24 hr.
Fig. 4. Calcium oxalate monohydrate (COM) crystal aggregation inhibi-
tion. The x-axis is UP concentration (nM), plotted on a log scale. The y-axis
is the degree of aggregation in the presence of uropontin (UP) as a
percent of the control without inhibitor, on a log scale. Results of all UP
samples tested are included on the graph. The solid line is the linear
regression (r2 5 0.66, F 5 209, P , 0.001).
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study, aggregation inhibition was determined for UP under con-
ditions that reduce the inhibition of crystal aggregation by THP.
Urinary prothrombin fragment 1 [18] and uronic acid rich protein
[19] are known to inhibit COM crystallization but have not been
quantified for all three aspects of crystallization.
Our measurements of growth inhibition give values for kDa of
5 to 36 nM. These are consistent with the value obtained by
Worcester, Kleinman and Beshensky [20] of 37 nM for mouse
osteopontin, and in the same range as our estimates of aggrega-
tion inhibition. From our measurements of urine UP excretion
rates and evidence that UP excretion does not vary with urine flow
rate [13], we calculated predicted inhibitions of growth and
aggregation using regression slopes and five assumed ranges of
24-hour urine volumes. For all subjects, aggregation and growth
inhibitions are predicted to be appreciable, even at 24-hour urine
volumes of 2.5 liters.
We found that UP inhibits COM nucleation by about 50% at a
concentration of 200 mM, which is 10-fold higher than the concen-
tration needed for an equivalent inhibition of growth or aggrega-
tion. At even 1 liter of daily urine volume, UP inhibition of
nucleation is therefore likely to be modest, given excretion rates
of 111 to 257 nM/24 hr. Since we did not measure nucleation
inhibition over a range of UP concentrations, we cannot be sure
about its variation with UP concentration, and detailed modeling
such as we performed for growth and aggregation is not appro-
priate.
Even though UP itself seems unlikely to cause more than 50%
COM nucleation inhibition in vivo, it may be very important.
Formation product ratio values in urine range at about 9 to 14,
compared to 6 to 8 in buffered solutions [21]. This means that
supersaturation must be raised by 20 to 40% higher in urine than
in buffer to initiate nucleation, a change in the range of our
observed effects of UP on self nucleation. Unfortunately, forma-
tion product ratios and rates of self nucleation cannot be directly
compared, so our inference is tenuous.
Our nucleation results differ from those of Worcester and
Beshensky [11], who found inhibition at as low as 5 to 11 nM
osteopontin. Our assays differ in that Worcester et al measured
the lag time to first fall of calcium concentration in an unseeded
solution of higher supersaturation than we used. We measured
the ligand consumption rate of a seeded system undergoing
secondary nucleation. Quite possibly, provision of seeds lowers
the energy requirements for nucleation, and therefore makes
inhibition more difficult. In addition they used osteopontin puri-
fied from mouse renal cortical cell cultures, not human UP, in
their assay. The two proteins may not be identical in their effects.
From their data, UP would seem as important an inhibitor of
nucleation as of growth. Further experiments using urine selec-
tively depleted of UP may provide a better resolution of this
difference in results, which may reflect the difference in technique
more than the protein biology of UP.
We conclude UP is a potent inhibitor of COM aggregation as
well as growth and nucleation. The urinary concentration of UP is
in the range in which its contribution to inhibition of growth and
aggregation are likely to be considerable. The contribution of UP
to inhibition of nucleation, is difficult to estimate, but may be
Fig. 5. Calcium oxalate monohydrate (COM) crystal aggregation inhibi-
tion as a function of uropontin (UP) inhibitory activity and urine flow.
The x-axis is the aggregation half inhibition concentration (nM) as
estimated from the log-log plot of aggregation inhibition versus concen-
tration of UP (note x-axis is on a powered scale). The y-axis is the
aggregation velocity expressed as percent control estimated for five
different assumed 24-hour urine volumes: (l) 0.5 liters of urine/24 hr; (F)
1 liter/24 hr; () 1.5 liters/24 hr; () 2 liters/24 hr; () 2.5 liters/24 hr.
Fig. 6. Calcium oxalate monohydrate (COM) nucleation inhibition. The
x-axis is the log of calcium consumption, the y-axis is time in minutes. Each
point on the plot is the mean 6 SEM for the time required for each step of
calcium addition in the presence of 200 mM uropontin (UP; E) and in the
absence of protein (F). The time required to reach each 0.25 mmole step
of calcium addition is longer in the presence of UP than in the control
(F 5 165, P , 0.001; by analysis of covariance using log Ca consumption
as the co-variate).
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significant. Whether UP excretion or inhibitory activity is different
in stone formers compared to normals will require further study.
Our results make UP a reasonable candidate as an important
natural defense of the kidney against COM crystallization. On the
one hand, it exhibits a wide range of effects, including growth,
aggregation and nucleation inhibition, and does so at concentra-
tions below those in urine. On the other hand, much remains to be
done. Direct comparison between normal and patient groups now
seems reasonable and possibly productive. Extrapolation from our
dilute buffered systems to urine, with its higher supersaturation
values and potential for protein to protein interaction is hazard-
ous, so that direct experiments with urine itself seem important.
What our results do establish is that this range of more extensive
research now seems a logical next step.
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